Pfizer to acquire minority stake in CStone Pharmaceuticals for $200m

This article was originally published here

Under the deal, CStone and Pfizer will involve in the development and commercialisation of CStone’s sugemalimab, an investigational anti-PD-L1 monoclonal antibody, in mainland China. They will also co-develop

The post Pfizer to acquire minority stake in CStone Pharmaceuticals for $200m appeared first on Pharmaceutical Business review.